ideasIdea

Alpha-emitting PSMA therapy for oligometastatic (few-lesion) prostate cancer

When prostate cancer comes back in just a handful of spots, doctors already zap those spots with precision radiotherapy. Adding a single dose of an alpha-particle radioactive drug at the same time, instead of the more established beta-particle version, might mop up cancer cells too small to see on a scan, because alpha radiation travels a much shorter distance and hits harder in that short range.

Oligorecurrent prostate cancer, typically defined as one to five metastatic lesions visible on PSMA PET after initial treatment, is increasingly treated with metastasis-directed stereotactic body radiotherapy (SBRT) to the visible spots, sometimes combined with a radioligand. Beta-emitting 177Lu-PSMA-I&T has already been tested as monotherapy in this setting: the randomised BULLSEYE trial (NCT04443062, 58 patients) compared two cycles of 177Lu-PSMA-I&T against standard-of-care deferred hormone therapy in oligometastatic hormone-sensitive disease. Alpha emitters have a much shorter particle range (tens to about 100 micrometres versus roughly a millimetre for lutetium-177's beta particles), which is physically well suited to killing scattered single cells or micrometastases invisible on the pre-treatment scan, but this physical argument has not yet been tested head-to-head against beta therapy in oligometastatic disease.

That direct comparison is now the subject of an open randomised trial: ANDROMEDA (NCT07150715, UCLA, led by Amar Kishan) randomises patients with one to five oligorecurrent lesions to either two cycles of 177Lu-PSMA-617 plus SBRT or a single cycle of 225Ac-PSMA-617 plus SBRT, with progression-free survival at 24 months (defined by PSMA PET/CT or biochemical progression) as the primary comparison. Separately, the ACCEL trial (NCT06229366) is testing a next-generation alpha ligand, 225Ac-PSMA-62 (LY4181530), specifically designed with a different linker to reduce the xerostomia and marrow toxicity associated with first-generation 225Ac-PSMA-617 or 225Ac-PSMA-I&T, in both oligometastatic hormone-sensitive and castration-resistant cohorts.

No trial has yet reported a comparative result between alpha- and beta-emitter approaches in oligometastatic disease; the rationale rests on radiobiological principles and on a strong first-generation alpha-emitter side-effect profile (particularly xerostomia) that newer ligands like PSMA-62 aim to address.

Hypothesis

Treating oligometastatic (one-to-five lesion) recurrent prostate cancer with a single dose of an alpha-emitting PSMA radioligand alongside stereotactic body radiotherapy to each visible lesion will control disease for longer than the same regimen using the beta-emitter lutetium-177-PSMA-617, because the alpha particle's short range concentrates a lethal dose in micrometastases that are below the resolution of the pre-treatment scan.

Rationale

The rationale is grounded in the established physical difference between alpha and beta emitters (alpha's roughly 100-micron range is a better physical match for single cells and micrometastases than beta's roughly 1 mm range), but no completed clinical trial has yet compared the two approaches in oligometastatic disease. The randomised ANDROMEDA trial (NCT07150715) is specifically designed to test this comparison directly, and the BULLSEYE trial already established that beta-emitter 177Lu-PSMA-I&T monotherapy alone can be tested against standard of care (deferred androgen deprivation) in this setting, providing the methodological precedent.

Proposed test

ANDROMEDA (NCT07150715), an open, randomised phase 2 trial at UCLA comparing two cycles of 177Lu-PSMA-617 plus SBRT against a single cycle of 225Ac-PSMA-617 plus SBRT in patients with one to five oligorecurrent lesions, with 24-month progression-free survival (by PSMA PET/CT or biochemical progression) as the primary comparison.

Maturity

early clinical

Who acts

research

Cost to try

Medium ($1M to $50M)

Years to first evidence